Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple Myeloma

Video

In Partnership With:

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Dickran G. Kazandjian, MD, professor of medicine, Myeloma Program, Sylvester Comprehensive Cancer Center, discusses the potential utility of bispecific T-cell engagers (BiTEs) in relapsed/refractory multiple myeloma.

BiTEs are monoclonal antibodies that utilize two binding domains, says Kazandjian. The first binds cytotoxic T cells to CD3, Kazandjian says. The second acts as a bridge to bring the T cell closer to a target on the myeloma cell, such as BCMA, Kazandjian says. In turn, this binding elicits an anticancer immune response, says Kazandjian.

Preliminary findings from studies evaluating BiTEs demonstrated high response rates in patients with heavily pretreated relapsed/refractory multiple myeloma, Kazandjian says. Moreover, some patients derived complete responses and minimal residual disease negativity, Kazandjian explains. It is currently too early to determine whether these responses are durable, but these initial results are encouraging, concludes Kazandjian.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute